Breaking News Instant updates and real-time market news.

BNGO

Bionano Genomics

$0.59 /

+0.0395 (+7.18%)

08:31
06/11/20
06/11
08:31
06/11/20
08:31

Bionano Genomics says data shows 100% concordance between Saphyr, standard tests

Bionano Genomics announced that three top cytogeneticists from leading institutions in The Netherlands and Germany presented data at the 2020 European Society of Human Genetics Virtual Conference showing 100% concordance between the Saphyr system and standard cytogenetic tests. The three separate presentations compared data generated with Bionano's Saphyr system against gold standard cytogenetic methods consisting of karyotyping, FISH, and/or chromosomal microarray in patients with leukemias and a variety of constitutional or inherited genetic disorders. In the first presentation, Dr. Alexander Hoischen from Radboud University Medical Center provided an update on his work on leukemias, which has been published, and showed 100% concordance between Bionano's Saphyr system and standard cytogenetic tests on 48 leukemia genomes. Additionally, he presented two research cases of families with undiagnosed genetic disorders, which were solved using the Saphyr system. The first case was on a rare and aggressive childhood tumor named Atypical Teratoid Rhabdoid Tumor, which is typically caused by an inherited mutation in the SMARCB1 gene. Saphyr detected an insertion in this gene in a family affected by ATRT, while Sanger sequencing, MLPA, whole exome and whole genome sequencing had failed to identify this variant. In a second family affected by intellectual disability, Saphyr identified a single de novo deletion in the child affecting the NSF gene. This deletion was confirmed to be de novo in the child through PCR validation. Dr. Hoischen concluded his presentation saying that Saphyr has the potential to replace classical cytogenetics methods, is able to detect hidden structural variants missed with all available NGS approaches, and may allow a cytogenetics revolution. In the second presentation, Dr. Uwe Heinrich, head of cytogenetics at MVZ Martinsried in Germany, presented six cases of patients with a variety of genetic disorders, with symptoms such as male infertility, microcephaly, developmental delay, seizures, and pigment anomalies. In all six cases, the Saphyr system identified the pathogenic variants, including balanced and unbalanced translocations, a paracentric inversion and mosaic duplication. In total 19 patient samples were analyzed, and the Saphyr system confirmed all known large rearrangements in these samples. Dr. Heinrich concluded that his team is planning to seek German accreditation for the Saphyr system this fall, to start offering Bionano's genome imaging as part of a stepwise diagnosis, and to eventually fully replace chromosomal microarray with the Saphyr system. In the third presentation, Dr. Kornelia Neveling from Radboud University discussed how Bionano improves structural variant detection for constitutional chromosomal aberrations. She compared the performance of Saphyr against standard cytogenetic methods in 40 samples with a variety of constitutional aberrations including deletions, duplications balanced and unbalanced translocations, inversions, ring chromosomes and aneuploidies in patients with intellectual disabilities and recurrent miscarriages. The Saphyr system showed 100% concordance with cytogenetic methods in these 40 samples and allowed for precise breakpoint mapping. Dr. Neveling plans to combine her data with a French multi-center study as part of the first international consortium to validate Saphyr-generated data for constitutional cytogenetic analysis. The combined study is expected to be submitted for publication during the second half of 2020, with results expected to be presented in a subsequent webinar. Later this week, Dr. Brandon LaBarge from Penn State Health and Penn State College of Medicine are scheduled to present research demonstrating the use of the Saphyr system to identify structural rearrangements in a variety of solid tumors. The talk entitled "Genome imaging of head and neck solid tumors: oropharyngeal, tongue, and thyroid cancers," is being hosted by LabRoots and is scheduled to take place on Friday, June 12, 2020 at 11 am ET. The presentation will be webcast, registration is available at labroots.com

  • 30

    Jun

BNGO Bionano Genomics
$0.59 /

+0.0395 (+7.18%)

04/08/20 Oppenheimer
Oppenheimer bullish on Bionano Genomics, initiates with an Outperform
04/08/20 Oppenheimer
Bionano Genomics initiated with an Outperform at Oppenheimer

TODAY'S FREE FLY STORIES

Recommendations
LivePerson price target raised to $50 from $43 at Benchmark » 07:15
07/06/20
07/06
07:15
07/06/20
07:15
LPSN

LivePerson

$43.94 /

+0.9 (+2.09%)

Benchmark analyst Mark…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LPSN LivePerson
$43.94 /

+0.9 (+2.09%)

LPSN LivePerson
$43.94 /

+0.9 (+2.09%)

07/01/20 KeyBanc
LivePerson price target raised to $48 from $38 at KeyBanc
06/25/20 Northland
LivePerson conversation volume spike could prompt early renewals, says Northland
06/22/20 B. Riley FBR
LivePerson price target raised to $43 from $36 at B. Riley FBR
06/17/20 Northland
LivePerson price target raised to $45 from $40 at Northland
LPSN LivePerson
$43.94 /

+0.9 (+2.09%)

LPSN LivePerson
$43.94 /

+0.9 (+2.09%)

LPSN LivePerson
$43.94 /

+0.9 (+2.09%)

LPSN LivePerson
$43.94 /

+0.9 (+2.09%)

Hot Stocks
Myriad Genetics announces collaboration with OptraHealth for Gene ChatBOT » 07:15
07/06/20
07/06
07:15
07/06/20
07:15
MYGN

Myriad Genetics

$11.53 /

+0.275 (+2.44%)

Myriad Genetics announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MYGN Myriad Genetics
$11.53 /

+0.275 (+2.44%)

MYGN Myriad Genetics
$11.53 /

+0.275 (+2.44%)

06/11/20 Piper Sandler
Palmetto coverage language unclear about Myriad's GeneSight, says Piper Sandler
05/06/20 JPMorgan
Myriad Genetics price target lowered to $12 from $14 at JPMorgan
05/06/20 Piper Sandler
Myriad Genetics price target lowered to $14 from $20 at Piper Sandler
03/06/20 JPMorgan
Myriad Genetics price target lowered to $14 from $17 at JPMorgan
MYGN Myriad Genetics
$11.53 /

+0.275 (+2.44%)

MYGN Myriad Genetics
$11.53 /

+0.275 (+2.44%)

Hot Stocks
Avrobio doses new patients in Gaucher disease, cystinosis clinical trials » 07:14
07/06/20
07/06
07:14
07/06/20
07:14
AVRO

Avrobio

$17.79 /

-0.05 (-0.28%)

AVROBIO announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AVRO Avrobio
$17.79 /

-0.05 (-0.28%)

AVRO Avrobio
$17.79 /

-0.05 (-0.28%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura Instinet
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
AVRO Avrobio
$17.79 /

-0.05 (-0.28%)

  • 13
    Feb
  • 17
    Jul
Downgrade
Veritone downgraded to Sell from Hold at Craig-Hallum » 07:14
07/06/20
07/06
07:14
07/06/20
07:14
VERI

Veritone

$15.63 /

-0.78 (-4.75%)

Craig-Hallum analyst Chad…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VERI Veritone
$15.63 /

-0.78 (-4.75%)

VERI Veritone
$15.63 /

-0.78 (-4.75%)

06/25/20 Roth Capital
Veritone price target raised to $18 from $7 at Roth Capital
11/08/19 JMP Securities
Veritone price target lowered to $7 from $10 at JMP Securities
11/07/19 Craig-Hallum
Veritone downgraded to Hold at Craig-Hallum after 'disapointing' Q3 results
11/07/19 Craig-Hallum
Veritone downgraded to Hold from Buy at Craig-Hallum
VERI Veritone
$15.63 /

-0.78 (-4.75%)

Initiation
Vroom initiated with an Outperform at Wedbush » 07:13
07/06/20
07/06
07:13
07/06/20
07:13
VRM

Vroom

$54.21 /

+0.045 (+0.08%)

Wedbush initiated…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VRM Vroom
$54.21 /

+0.045 (+0.08%)

06:41 Today Stifel
Stifel starts Vroom at Buy, sees premium as justified
06:40 Today JMP Securities
Vroom initiated with an Outperform at JMP Securities
06:19 Today Wells Fargo
Vroom initiated with an Overweight at Wells Fargo
04:48 Today Baird
Vroom initiated with an Outperform at Baird
  • 09
    Jun
VRM Vroom
$54.21 /

+0.045 (+0.08%)

VRM Vroom
$54.21 /

+0.045 (+0.08%)

Upgrade
Acasti Pharma upgraded to Buy from Neutral at B. Riley FBR » 07:12
07/06/20
07/06
07:12
07/06/20
07:12
ACST

Acasti Pharma

$0.53 /

+0.0158 (+3.05%)

B. Riley FBR analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ACST Acasti Pharma
$0.53 /

+0.0158 (+3.05%)

ACST Acasti Pharma
$0.53 /

+0.0158 (+3.05%)

02/18/20 H.C. Wainwright
Acasti Pharma price target lowered to $3 from $6 at H.C. Wainwright
01/13/20 Roth Capital
Amarin's Vascepa now the 'go-to' after competitor failures, says Roth Capital
01/13/20 Stifel
Amarin should rally on failure of two potential competitors, says Stifel
01/13/20 B. Riley FBR
Acasti Pharma downgraded to Neutral from Buy at B. Riley FBR
ACST Acasti Pharma
$0.53 /

+0.0158 (+3.05%)

ACST Acasti Pharma
$0.53 /

+0.0158 (+3.05%)

Hot Stocks
Precision BioSciences regains rights to in vivo HBV program » 07:11
07/06/20
07/06
07:11
07/06/20
07:11
DTIL

Precision BioSciences

$8.44 /

+0.06 (+0.72%)

, GILD

Gilead

$76.31 /

+0.28 (+0.37%)

Precision BioSciences…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

05/18/20 H.C. Wainwright
Precision BioSciences could have 'significant upside,' says H.C. Wainwright
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
03/04/20 Stifel
Precision BioSciences initiated with a Buy at Stifel
GILD Gilead
$76.31 /

+0.28 (+0.37%)

06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

Recommendations
Broadcom price target raised to $322 from $286 at Goldman Sachs » 07:11
07/06/20
07/06
07:11
07/06/20
07:11
AVGO

Broadcom

$315.33 /

+2.62 (+0.84%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AVGO Broadcom
$315.33 /

+2.62 (+0.84%)

AVGO Broadcom
$315.33 /

+2.62 (+0.84%)

06/26/20
Fly Intel: Top five analyst upgrades
06/26/20 Evercore ISI
Evercore upgrades Broadcom to Outperform, sees Apple sales driving upside
06/26/20 Evercore ISI
Broadcom upgraded to Outperform from In Line at Evercore ISI
06/22/20 Mizuho
Broadcom price target raised to $350 from $325 at Mizuho
AVGO Broadcom
$315.33 /

+2.62 (+0.84%)

AVGO Broadcom
$315.33 /

+2.62 (+0.84%)

AVGO Broadcom
$315.33 /

+2.62 (+0.84%)

AVGO Broadcom
$315.33 /

+2.62 (+0.84%)

Recommendations
CME Group price target lowered to $176 from $186 at Wells Fargo » 07:11
07/06/20
07/06
07:11
07/06/20
07:11
CME

CME Group

$165.26 /

-3.55 (-2.10%)

Wells Fargo analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CME CME Group
$165.26 /

-3.55 (-2.10%)

CME CME Group
$165.26 /

-3.55 (-2.10%)

06/24/20 JPMorgan
CME Group shares could continue to underperform, says JPMorgan
06/23/20 Credit Suisse
CME Group price target lowered to $183 from $190 at Credit Suisse
06/22/20 Goldman Sachs
CME Group price target lowered to $170 from $175 at Goldman Sachs
04/28/20 JPMorgan
CME Group interest rate business at risk, says JPMorgan
CME CME Group
$165.26 /

-3.55 (-2.10%)

CME CME Group
$165.26 /

-3.55 (-2.10%)

CME CME Group
$165.26 /

-3.55 (-2.10%)

CME CME Group
$165.26 /

-3.55 (-2.10%)

Hot Stocks
Anavex commences enrollment in ANAVEX3-71 trial » 07:10
07/06/20
07/06
07:10
07/06/20
07:10
AVXL

Anavex

$4.96 /

-0.03 (-0.60%)

Anavex announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AVXL Anavex
$4.96 /

-0.03 (-0.60%)

AVXL Anavex
$4.96 /

-0.03 (-0.60%)

03/16/20
Fly Intel: Top five analyst initiations
03/16/20 H.C. Wainwright
Anavex initiated with a Buy at H.C. Wainwright
02/27/20
Fly Intel: Top five analyst initiations
02/27/20 Cantor Fitzgerald
Anavex initiated with an Overweight and $11 target at Cantor Fitzgerald
AVXL Anavex
$4.96 /

-0.03 (-0.60%)

AVXL Anavex
$4.96 /

-0.03 (-0.60%)

AVXL Anavex
$4.96 /

-0.03 (-0.60%)

Recommendations
Skyworks price target raised to $136 from $107 at Goldman Sachs » 07:10
07/06/20
07/06
07:10
07/06/20
07:10
SWKS

Skyworks

$128.37 /

+2.55 (+2.03%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SWKS Skyworks
$128.37 /

+2.55 (+2.03%)

SWKS Skyworks
$128.37 /

+2.55 (+2.03%)

06/26/20 Cowen
Skyworks price target raised to $130 from $110 at Cowen
06/18/20 Argus
Skyworks price target raised to $146 from $112 at Argus
06/08/20 B. Riley FBR
Skyworks price target raised to $165 from $125 at B. Riley FBR
06/02/20 Mizuho
Skyworks price target raised to $127 from $112 at Mizuho
SWKS Skyworks
$128.37 /

+2.55 (+2.03%)

SWKS Skyworks
$128.37 /

+2.55 (+2.03%)

SWKS Skyworks
$128.37 /

+2.55 (+2.03%)

Hot Stocks
Dow Inc. to sell infrastructure assets, equipment to Watco for $310M in proceeds » 07:08
07/06/20
07/06
07:08
07/06/20
07:08
DOW

Dow Inc.

$41.59 /

+0.88 (+2.16%)

Dow announced that it has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DOW Dow Inc.
$41.59 /

+0.88 (+2.16%)

DOW Dow Inc.
$41.59 /

+0.88 (+2.16%)

06/26/20 JPMorgan
Dow Inc. price target raised to $35 from $33 at JPMorgan
06/25/20 SunTrust
Dow Inc. price target raised to $43 from $37 at SunTrust
06/25/20 Deutsche Bank
Dow Inc. price target raised to $45 from $42 at Deutsche Bank
05/06/20
Fly Intel: Top five analyst downgrades
DOW Dow Inc.
$41.59 /

+0.88 (+2.16%)

DOW Dow Inc.
$41.59 /

+0.88 (+2.16%)

DOW Dow Inc.
$41.59 /

+0.88 (+2.16%)

DOW Dow Inc.
$41.59 /

+0.88 (+2.16%)

Recommendations
Qorvo price target raised to $137 from $115 at Goldman Sachs » 07:08
07/06/20
07/06
07:08
07/06/20
07:08
QRVO

Qorvo

$110.35 /

+2.1 (+1.94%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
QRVO Qorvo
$110.35 /

+2.1 (+1.94%)

QRVO Qorvo
$110.35 /

+2.1 (+1.94%)

06/16/20 Morgan Stanley
Qorvo upgraded to Overweight on expected mobile recovery at Morgan Stanley
06/16/20 Morgan Stanley
Qorvo upgraded to Overweight from Equal Weight at Morgan Stanley
06/15/20 Cowen
Qorvo price target raised to $120 from $115 at Cowen
05/08/20 Craig-Hallum
Qorvo price target raised to $120 from $100 at Craig-Hallum
QRVO Qorvo
$110.35 /

+2.1 (+1.94%)

QRVO Qorvo
$110.35 /

+2.1 (+1.94%)

QRVO Qorvo
$110.35 /

+2.1 (+1.94%)

QRVO Qorvo
$110.35 /

+2.1 (+1.94%)

Hot Stocks
Aurora Cannabis appoints Miguel Martin as Chief Commercial Officer » 07:08
07/06/20
07/06
07:08
07/06/20
07:08
ACB

Aurora Cannabis

$12.24 /

-0.03 (-0.24%)

Aurora Cannabis announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ACB Aurora Cannabis
$12.24 /

-0.03 (-0.24%)

ACB Aurora Cannabis
$12.24 /

-0.03 (-0.24%)

06/24/20
Fly Intel: Top five analyst upgrades
06/24/20 Cantor Fitzgerald
Aurora Cannabis price target raised to C$29 from C$27 at Cantor Fitzgerald
06/24/20 Stifel
Aurora Cannabis upgraded to Hold from Sell at Stifel
05/22/20 CIBC
Aurora Cannabis price target raised to C$24 from C$14 at CIBC
ACB Aurora Cannabis
$12.24 /

-0.03 (-0.24%)

ACB Aurora Cannabis
$12.24 /

-0.03 (-0.24%)

ACB Aurora Cannabis
$12.24 /

-0.03 (-0.24%)

ACB Aurora Cannabis
$12.24 /

-0.03 (-0.24%)

Hot Stocks
Regeneron announces start of REGN-COV2 Phase 3 COVID-19 prevention trial » 07:06
07/06/20
07/06
07:06
07/06/20
07:06
REGN

Regeneron

$620.76 /

+11.54 (+1.89%)

Regeneron Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
REGN Regeneron
$620.76 /

+11.54 (+1.89%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
REGN Regeneron
$620.76 /

+11.54 (+1.89%)

  • 27
    May
REGN Regeneron
$620.76 /

+11.54 (+1.89%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

Hot Stocks
Staar Surgical announces Patrick Williams as CFO » 07:05
07/06/20
07/06
07:05
07/06/20
07:05
STAA

Staar Surgical

$61.70 /

+1.29 (+2.14%)

Staar Surgical announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
STAA Staar Surgical
$61.70 /

+1.29 (+2.14%)

STAA Staar Surgical
$61.70 /

+1.29 (+2.14%)

06/24/20 BTIG
Staar Surgical downgraded to Neutral from Buy at BTIG
06/15/20 Jefferies
Staar Surgical initiated with a Buy at Jefferies
03/04/20
BTIG healthcare analysts to hold an analyst/industry conference call
01/31/20 Benchmark
Too early to call China emergency impact on Staar Surgical, says Benchmark
STAA Staar Surgical
$61.70 /

+1.29 (+2.14%)

General news
FX Update: Risk-on positioning has been ensuing » 07:05
07/06/20
07/06
07:05
07/06/20
07:05

FX Update: Risk-on…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Earnings
Sally Beauty reports preliminary Q3 revenue $705M, consensus $653.39M  07:03
07/06/20
07/06
07:03
07/06/20
07:03
SBH

Sally Beauty

$13.08 /

+0.17 (+1.32%)

 
ShowHide Related Items >><<
SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

06/04/20 Oppenheimer
Sally Beauty upgraded to Outperform at Oppenheimer
06/04/20 Oppenheimer
Sally Beauty upgraded to Outperform from Perform at Oppenheimer
04/27/20 DA Davidson
Sally Beauty price target lowered to $10 from $14.50 at DA Davidson
04/20/20 Raymond James
Sally Beauty preliminary Q2 not as bad as feared, says Raymond James
SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

Syndicate
Akero announces proposed public offering of 4.75M shares of common stock » 07:03
07/06/20
07/06
07:03
07/06/20
07:03
AKRO

Akero Therapeutics

$33.13 /

-0.36 (-1.07%)

J.P. Morgan Securities,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AKRO Akero Therapeutics
$33.13 /

-0.36 (-1.07%)

AKRO Akero Therapeutics
$33.13 /

-0.36 (-1.07%)

07/01/20 JPMorgan
Akero Therapeutics price target raised to $41 from $28 at JPMorgan
07/01/20 Jefferies
Akero Therapeutics price target raised to $48 from $31 at Jefferies
07/01/20 Canaccord
Akero Therapeutics price target raised to $51 from $36 at Canaccord
07/01/20 H.C. Wainwright
Akero Therapeutics price target raised to $45 from $33 at H.C. Wainwright
AKRO Akero Therapeutics
$33.13 /

-0.36 (-1.07%)

AKRO Akero Therapeutics
$33.13 /

-0.36 (-1.07%)

AKRO Akero Therapeutics
$33.13 /

-0.36 (-1.07%)

Hot Stocks
Regeneron announces start of REGN-COV2 Phase 3 COVID-19 prevention trial  07:03
07/06/20
07/06
07:03
07/06/20
07:03
REGN

Regeneron

$620.76 /

+11.54 (+1.89%)

 
ShowHide Related Items >><<
REGN Regeneron
$620.76 /

+11.54 (+1.89%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
REGN Regeneron
$620.76 /

+11.54 (+1.89%)

  • 27
    May
REGN Regeneron
$620.76 /

+11.54 (+1.89%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

Syndicate
Vir Biotechnology files to sell 6.2M shares of common stock » 07:02
07/06/20
07/06
07:02
07/06/20
07:02
VIR

Vir Biotechnology

$40.27 /

+0.65 (+1.64%)

Goldman Sachs & Co.…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VIR Vir Biotechnology
$40.27 /

+0.65 (+1.64%)

VIR Vir Biotechnology
$40.27 /

+0.65 (+1.64%)

05/13/20 Barclays
Vir Biotechnology price target raised to $44 from $41 at Barclays
03/19/20 JPMorgan
JPMorgan downgrades Vir Biotechnology to Underweight after 290% rally
03/19/20 JPMorgan
Vir Biotechnology downgraded to Underweight from Neutral at JPMorgan
03/13/20 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
VIR Vir Biotechnology
$40.27 /

+0.65 (+1.64%)

  • 11
    Oct
VIR Vir Biotechnology
$40.27 /

+0.65 (+1.64%)

VIR Vir Biotechnology
$40.27 /

+0.65 (+1.64%)

VIR Vir Biotechnology
$40.27 /

+0.65 (+1.64%)

Upgrade
Infosys upgraded to Conviction Buy from Buy at Goldman Sachs » 07:02
07/06/20
07/06
07:02
07/06/20
07:02
INFY

Infosys

$9.92 /

+0.23 (+2.37%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
INFY Infosys
$9.92 /

+0.23 (+2.37%)

INFY Infosys
$9.92 /

+0.23 (+2.37%)

04/20/20 Stifel
Near-term will be difficult for Infosys, opportunity exists, says Stifel
02/20/20 JPMorgan
JPMorgan names Infosys top pick in India IT Services, Wipro top avoid
02/20/20 JPMorgan
Infosys initiated with an Overweight at JPMorgan
02/17/20 Goldman Sachs
Infosys upgraded to Buy from Neutral at Goldman Sachs
INFY Infosys
$9.92 /

+0.23 (+2.37%)

Hot Stocks
Becton Dickinson launches portable, rapid point-of-care COVID-19 antigen test » 07:01
07/06/20
07/06
07:01
07/06/20
07:01
BDX

Becton Dickinson

$245.09 /

+3.57 (+1.48%)

BD announced that the FDA…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BDX Becton Dickinson
$245.09 /

+3.57 (+1.48%)

BDX Becton Dickinson
$245.09 /

+3.57 (+1.48%)

07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
07/02/20 Wells Fargo
Becton rapid antigen COVID test may be available very soon, says Wells Fargo
06/25/20 Raymond James
Becton Dickinson price target lowered to $265 from $290 at Raymond James
06/01/20
Fly Intel: Top five analyst initiations
BDX Becton Dickinson
$245.09 /

+3.57 (+1.48%)

  • 21
    May
BDX Becton Dickinson
$245.09 /

+3.57 (+1.48%)

Hot Stocks
Sally Beauty provides update on COVID-19 impact » 07:00
07/06/20
07/06
07:00
07/06/20
07:00
SBH

Sally Beauty

$13.08 /

+0.17 (+1.32%)

Sally Beauty provided an…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

06/04/20 Oppenheimer
Sally Beauty upgraded to Outperform at Oppenheimer
06/04/20 Oppenheimer
Sally Beauty upgraded to Outperform from Perform at Oppenheimer
04/27/20 DA Davidson
Sally Beauty price target lowered to $10 from $14.50 at DA Davidson
04/20/20 Raymond James
Sally Beauty preliminary Q2 not as bad as feared, says Raymond James
SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

Recommendations
Guggenheim 'loves' Dominion gas transmission sale, decision to scrap pipeline » 07:00
07/06/20
07/06
07:00
07/06/20
07:00
D

Dominion

$82.68 /

+0.32 (+0.39%)

, BRK.A

Berkshire Hathaway

$267,661.14 /

+751.14 (+0.28%)

, DUK

Duke Energy

$81.84 /

-0.1 (-0.12%)

Guggenheim analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
D Dominion
$82.68 /

+0.32 (+0.39%)

BRK.A Berkshire Hathaway
$267,661.14 /

+751.14 (+0.28%)

DUK Duke Energy
$81.84 /

-0.1 (-0.12%)

D Dominion
$82.68 /

+0.32 (+0.39%)

06/09/20 Seaport Global
Dominion initiated with a Buy at Seaport Global
05/29/20 Wolfe Research
Dominion downgraded to Peer Perform from Outperform at Wolfe Research
05/14/20 Credit Suisse
Dominion price target raised to $85 from $80 at Credit Suisse
04/24/20 Morgan Stanley
Federal support for renewables could come in summer, says Morgan Stanley
BRK.A Berkshire Hathaway
$267,661.14 /

+751.14 (+0.28%)

04/06/20 Citi
Delta not 'broken story' but share weakness may persist, says Citi
DUK Duke Energy
$81.84 /

-0.1 (-0.12%)

06/09/20 Seaport Global
Duke Energy initiated with a Neutral at Seaport Global
05/20/20 Wells Fargo
Duke Energy price target lowered to $88 from $108 at Wells Fargo
04/24/20 Morgan Stanley
Federal support for renewables could come in summer, says Morgan Stanley
03/12/20 Barclays
Duke Energy downgraded to Equal Weight from Overweight at Barclays
D Dominion
$82.68 /

+0.32 (+0.39%)

BRK.A Berkshire Hathaway
$267,661.14 /

+751.14 (+0.28%)

DUK Duke Energy
$81.84 /

-0.1 (-0.12%)

  • 19
    Nov
D Dominion
$82.68 /

+0.32 (+0.39%)

BRK.A Berkshire Hathaway
$267,661.14 /

+751.14 (+0.28%)

DUK Duke Energy
$81.84 /

-0.1 (-0.12%)

D Dominion
$82.68 /

+0.32 (+0.39%)

BRK.A Berkshire Hathaway
$267,661.14 /

+751.14 (+0.28%)

DUK Duke Energy
$81.84 /

-0.1 (-0.12%)

D Dominion
$82.68 /

+0.32 (+0.39%)

DUK Duke Energy
$81.84 /

-0.1 (-0.12%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.